(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine + Comparator: placebo (unspecified)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Condylomata Acuminata
Conditions
Condylomata Acuminata
Trial Timeline
Sep 3, 2004 → Apr 3, 2017
NCT ID
NCT00090285About (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine + Comparator: placebo (unspecified)
(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine + Comparator: placebo (unspecified) is a phase 3 stage product being developed by Merck for Condylomata Acuminata. The current trial status is completed. This product is registered under clinical trial identifier NCT00090285. Target conditions include Condylomata Acuminata.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00090285 | Phase 3 | Completed |